New Delhi: Indian Medicinal Controller General (DCGI) has given permission to conduct a trial of Bridging Phase III from Sputnik Light in the Indian population.
Sputnik lights are a single-19 dose vaccine of the Russian vaccine sputnik.
The nod came after the latest research published in a medical journal, Lancet said that sputnik light showed the efficacy of 78.6 to 83.7 percent against Covid-19, significantly higher than most vaccines of two shots.
The Standard Control Center drug subject committee (CDSCO) in July has refused to authorize emergency use to Sputnik-Light, put aside the need for phase III test behavior from the Russian vaccine in the country.
The Committee has noted that sputnik light is the same as component-1 Sputnik V and its safety and immunogenicity data in the Indian population has been produced in the trial.
This study was conducted on at least 40,000 parents in Argentina.
Sputnik Light also reduces hospitalization among the target population at 82.1-87.6 percent, the study said.
Russian Direct Investment Fund (RDIF) last year partnered with the Laboratory of Dr.
Reddy to conduct a phase III test from Sputnik V vaccine in India.
In April, Sputnik V accepted the authorization of emergency use in India.
Reddy gave the first dose of the vaccine in Hyderabad under the pilot limited on May 14.
Sputnik single dose vaccine gets a DCGI nod for phase-III trials in India
